Rasio utang jangka dawa marang modal phiopharma.com (PHIO)

A stable team of geneticists ensures Phio Pharmaceuticals (PHIO) achieves steady progress in oncology, despite challenges with international logistics and patent disputes. Monitoring the long-term debt-to-equity ratio confirms financial stability, where 0.00 serves as the final level marker. Since the efficacy of RNA therapy is independent of market cycles, macroeconomics only affects the cost of attracting investment.

Phio Pharmaceuticals (PHIO) invests in innovative RNA technologies to combat oncology, requiring significant capital expenditures. This long-term debt-to-equity ratio measures the proportion of borrowed funds with a maturity exceeding one year relative to shareholders' equity. The trend in the long-term debt-to-equity ratio reflects the balance between financial leverage and the risk profile. Low values confirm development autonomy driven by intellectual property, which stabilizes the issuer's market capitalization.